NCT04202835View on ClinicalTrials.gov

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

May 18, 2024

Study Completion Date

February 7, 2026

Conditions
Acute LeukemiaMyelodysplasiaChronic Graft-versus-host-disease
Interventions
DRUG

Cyclophosphamide

Post Transplant Cyclophosphamide

DRUG

Anti-Thymocyte globulin (rabbit)

Anti-Thymocyte Globulin (rabbit, Thymoglobulin)

Trial Locations (9)

2010

Kinghorn Cancer Centre, St Vincent's Health Network, Darlinghurst

2065

Royal North Shore Hospital, St Leonards

3121

Australasian Leukaemia and Lymphoma Group, Melbourne

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 2Y9

Queen Elizabeth II Health Sciences Centre, Halifax

L8V 1C3

Juravinski Hospital and Cancer Centre, Hamilton

N6A 5W9

London Health Sciences Centre, London

G1R 2J6

Hôpital de l'Enfant-Jésus, Québec

S7N 4H4

Saskatchewan Cancer Agency, Saskatoon

Sponsors
All Listed Sponsors
collaborator

Cell Therapy Transplant Canada

UNKNOWN

collaborator

Sanofi

INDUSTRY

collaborator

Ozmosis Research Inc.

INDUSTRY

lead

McMaster University

OTHER